Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
Hum Pathol. 2010 Apr;41(4):477-84. doi: 10.1016/j.humpath.2009.10.004. Epub 2009 Dec 11.
Insulin-like growth factor II mRNA binding protein 3 is an oncofetal protein that is expressed in multiple malignancies. This study aimed to determine the correlation of insulin-like growth factor II mRNA binding protein 3 expression with histologic grade of lung adenocarcinoma. Eighty-nine cases, including 11 atypical adenomatous hyperplasias, 10 pure bronchioloalveolar carcinomas, 36 well-differentiated adenocarcinomas and 41 moderately or poorly differentiated adenocarcinomas, were immunohistochemically studied using a monoclonal antibody against insulin-like growth factor II mRNA binding protein 3. Twenty-nine (70.7%) of 41 moderately to poorly differentiated adenocarcinomas were positive for insulin-like growth factor II mRNA binding protein 3, with 26 (89.7%) tumors demonstrating either a strong staining or staining in greater than 30% of tumor cells. Four (40.0%) of 10 bronchioloalveolar carcinomas and 13 (36.1%) of 36 well-differentiated adenocarcinomas exhibited insulin-like growth factor II mRNA binding protein 3 positivity with a variable degree and percentage of tumor cells staining. When bronchioloalveolar carcinomas were present in a pure form or as a component of adenocarcinomas, positive insulin-like growth factor II mRNA binding protein 3 staining was always patchy, with less than 20% of tumor cells stained. Overall, the frequency of positive insulin-like growth factor II mRNA binding protein 3 staining was lower in bronchioloalveolar carcinomas and well-differentiated adenocarcinomas compared to moderately/poorly differentiated adenocarcinomas (P < .01). No insulin-like growth factor II mRNA binding protein 3 signal was detected in any case of atypical adenomatous hyperplasia. These findings show that insulin-like growth factor II mRNA binding protein 3 is strongly and diffusely expressed in a large proportion of moderately/poorly differentiated lung adenocarcinomas, in particular in the solid component of mixed subtype adenocarcinomas, less frequently expressed in well-differentiated adenocarcinomas and bronchioloalveolar carcinomas, and negative in atypical adenomatous hyperplasias. The higher frequency of expression in moderately/poorly differentiated adenocarcinomas suggests that insulin-like growth factor II mRNA binding protein 3 expression may be associated with an aggressive biological behavior.
胰岛素样生长因子 II mRNA 结合蛋白 3 是一种癌胚蛋白，在多种恶性肿瘤中表达。本研究旨在确定胰岛素样生长因子 II mRNA 结合蛋白 3 的表达与肺腺癌组织学分级的相关性。使用针对胰岛素样生长因子 II mRNA 结合蛋白 3 的单克隆抗体对 89 例病例进行免疫组织化学研究，包括 11 例非典型腺瘤性增生、10 例纯细支气管肺泡癌、36 例高分化腺癌和 41 例中低分化腺癌。41 例中低分化腺癌中有 29 例（70.7%）对胰岛素样生长因子 II mRNA 结合蛋白 3 呈阳性，其中 26 例（89.7%）肿瘤表现为强染色或>30%的肿瘤细胞染色。10 例细支气管肺泡癌中有 4 例（40.0%）和 36 例高分化腺癌中有 13 例（36.1%）显示胰岛素样生长因子 II mRNA 结合蛋白 3 阳性，肿瘤细胞的染色程度和百分比存在差异。当细支气管肺泡癌以纯型或腺癌成分存在时，阳性胰岛素样生长因子 II mRNA 结合蛋白 3 染色总是呈斑片状，<20%的肿瘤细胞染色。总体而言，与中低分化腺癌相比，细支气管肺泡癌和高分化腺癌中阳性胰岛素样生长因子 II mRNA 结合蛋白 3 染色的频率较低（P<.01）。在任何非典型腺瘤性增生病例中均未检测到胰岛素样生长因子 II mRNA 结合蛋白 3 信号。这些发现表明，胰岛素样生长因子 II mRNA 结合蛋白 3 在很大比例的中低分化肺腺癌中强烈且弥漫表达，特别是在混合亚型腺癌的实性成分中，在高分化腺癌和细支气管肺泡癌中表达较少，在非典型腺瘤性增生中为阴性。在中低分化腺癌中表达频率较高表明，胰岛素样生长因子 II mRNA 结合蛋白 3 的表达可能与侵袭性生物学行为有关。
